| |
 |
In our December issue of Pharmaceutical Executive
FEATURES
Cover Story
Science and Finance: The Biotech Blend–A CFO Roundtable
Lisa Henderson
Financial leaders from clinical-stage biopharma gather to discuss the critical role of finance and accounting (F&A) in supporting and sustaining the science at the forefront of engagement with investors.
Download the digital issue |
ADVERTISEMENT
Patient Assistance Centers of Excellence: The Next Generation of Brand Support
On Demand
 Learn More |
RWE
Securing a Winning Strategy for Real-World Evidence
Julian Upton
While the increasing importance of real-world evidence (RWE) is widely acknowledged, the dramatic shift required by pharma to embed meaningful and holistic benefits from this capability is still a work in progress.
Download the digital issue |
| |
 |
RWE
Answering Rare Disease Questions with RWE
Julian Upton
Sonalee Agarwal, head of value and evidence strategy for Alnylam, talks with Pharm Exec about the role of real-world evidence in the rare and ultra-rare disease space.
Download the digital issue |
Pricing
Measuring the Probability of Pricing and Access Success
Jonathan Chee, Betty Pio, Julia Ehrhardt, Evelyn Siu
There is still no structured method of assessing pricing and access risk for drug manufacturers. Presented here is a straightforward measure for integrating pricing and access risk into portfolio planning and decision-making.
Download the digital issue |
ALSO IN THIS ISSUE
Attack Mounts on Biopharma Drug Prices
Jill Wechsler
Efforts intensify to bring outlays more in line with global trends…Read more
Europe's Digital Health Path Still at a Crossroads
Reflector
The Commission's gestures toward enacting formal standards to digitize health records are masking wider policy gaps…Read more
Can New Tech Outsmart Status Quo?
Lisa Henderson
In pharma, there may be hope that companies' and the industry's ability to adapt to change may finally be catching up to the pace of new and intelligent uses of technology and clinical data …Read more
|
